Table 1 Baseline characteristics of patients initially without PAD and of those who did and did not survive without PAD during 12 years follow up
All without PAD at baseline | PAD, amputation or death during 12 years follow up | Alive without PAD or amputation during follow up | ||||
|---|---|---|---|---|---|---|
N or mean | Proportion in %; [95% CI for proportion] or [95% CI for mean] | N or mean | Proportion in %; [95% CI for proportion] or [95% CI for mean] | N or mean | Proportion in %; [95% CI for proportion] or [95% CI for mean] | |
n | 146 | 100% | 53 | 36.3% | 93 | 63.7% |
Age (years) | 61.6 | [60.5–62.8] | 64.2 | [62.4–66.0] | 61.2 | [59.6–61.7] |
Sex (male) | 90 | 62%; [54–69%] | 36 | 68%; [55–79%] | 54 | 58%; [48–68%] |
Diabetes duration (years) | 7.1 | [6.2–8.0] | 7.9 | [6.1–9.6] | 6.7 | [5.6–7.7] |
Body mass index | 29.3 | [28.5–30.1] | 28.8 | [27.3–30.3] | 29.7 | [28.7–30.6] |
Hypertensiona | 95 | 65%; [57–72%] | 33 | 62%; [49–74%] | 62 | 67%; [57–75%] |
Systolic blood pressure (mmHg) | 148 | [145–152] | 150 | [144–157] | 147 | [142–151] |
Present smoker | 43 | 30%; [23–38%] | 22 | 42%; [30–56%]b | 21 | 23%; [15–32%] |
Framingham 10-year CV risk score | 37% | [33–40%] | 46% | [40–52%] | 32% | [29–35%]c |
Retinopathy | 36 | 30%; [22–38%] | 16 | 36%; [23–50%] | 20 | 26%; [17–37%] |
Nephropathyd | 12 | 8%; [5–14%] | 5 | 9%; [4–20%] | 7 | 8%; [4–15%] |
Peripheral neuropathy | 92 | 63%; [55–70%] | 35 | 66%; [53–77%] | 57 | 61%; [51–71%] |
HbA1c mmol/mol (IFCC) | 56 | [54–58] | 58 | [54–63] | 55 | [52–57] |
Cholesterol (mmol/L) | 4.96 | [4.79–5.13] | 4.84 | [4.52–5.16] | 4.99 | [4.79–5.20] |
LDL-cholesterol (mmol/L) | 3.08 | [2.95–3.23] | 3.02 | [2.76–3.28] | 3.09 | [2.92–3.26] |
HDL-cholesterol (mmol/L) | 1.22 | [1.16–1.28] | 1.13 | [1.02–1.23] | 1.27 | [1.19–1.34] |
Triglycerides (mmol/L) | 1.72 | [1.52–1.92] | 1.85 | [1.40–2.29] | 1.67 | [1.47–1.87] |
Creatinine (µmol/mL) | 78 | [75–82] | 81 | [73–89] | 76 | [73–80] |
esRAGE (ng/mL) | 0.32 | [0.28–0.36] | 0.30 | [0.27–0.33] | 0.32 | [0.27–0.38] |
S100A12 (ng/mL) | 56 | [41–72] | 78 | [37–119] | 44 | [33–55] |
CML (µg/mL) | 2.05 | [1.67–2.42] | 2.05 | [1.25–2.86] | 2.03 | [1.63–2.43] |